{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-022898","form_type":"8-K","ticker":"CURX","cik":"0002025942","company_name":"Curanex Pharmaceuticals Inc","filed_at":"2026-05-14T13:15:35+00:00","discovered_at":"2026-05-14T13:16:00.492847+00:00","generated_at":"2026-05-14T13:17:40.098399+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Curanex completes key Phyto-N milestones; plans Q4 2026 IND for ulcerative colitis","bullets":["Completed GMP pilot-scale batch of Phyto-N in February 2026 to support IND-enabling studies.","28-day dose-range finding toxicology study in rats and dogs showed no adverse findings at any dose.","Expanded pipeline to include cancer cachexia; global market estimated at $2.54B in 2024.","Cash and equivalents of ~$4.0M as of March 31, 2026, sufficient for near-term development activities.","Targeting Q4 2026 IND submission for ulcerative colitis; Phase I trial to follow FDA review."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022898","json":"https://secwatch.observer/filing/0001493152-26-022898.json","markdown":"https://secwatch.observer/filing/0001493152-26-022898.md","text":"https://secwatch.observer/filing/0001493152-26-022898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2025942/000149315226022898/0001493152-26-022898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2025942/000149315226022898/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T13:17:40.098399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}